Albert Labs is the first psychedelic company to leverage Real World Evidence (RWE) Studies to accelerate access to approved psychedelic medicines in hospital settings across the UK and Europe to treat mental health indications with urgent and high unmet needs. Albert will own the wide dataset collected in the studies to develop an IP stack around unique formulation and delivery mechanisms of its approved psychedelics drug therapy.
A laboratory based, clinical research and drug development enterprise, focused on improving patient access to psychedelic assisted therapies. Starting with cancer-related anxiety, depression and existential crisis, Albert Labs will bring proprietary natural psilocybin-assisted therapy to the UK and Europe before expanding globally. Albert Labs is going through an RTO with a listing expected soon. More details can be found in our previous news release.
Albert Labs has submitted applications for psychedelic research and a dealer’s license which will allow the Company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline in its lab in Burnaby, BC Canada. These Health Canada licenses will also allow the company to export, test, and conduct R&D on these controlled substances.